MATTHEW V. LORENZI, Ph.D.
SOLID TUMOR TARGETED THERAPIES DISEASE AREA STRONGHOLD LEADER
Matthew Lorenzi, Ph.D. is Vice President, Solid Tumor Targeted Therapies Disease Area Stronghold Leader in the Oncology Therapeutic Area at Janssen Research & Development, LLC. In this role, Matthew is responsible for the strategic direction and execution of the Solid Tumor Disease Area portfolio, from early drug discovery efforts through clinical development. During his tenure at Janssen, Matthew advanced strong discovery and translational research to deliver a robust preclinical and clinical pipeline of novel immunotherapies and targeted therapies.
Prior to joining Janssen, Matthew was a senior oncology leader at Bristol Myers Squibb, where he directed teams focused on small molecule and biologics-based drug discovery and development. Within these roles, he brought strong scientific and strategic leadership to successfully deliver multiple therapies into and through clinical development.
Matthew received his doctorate in Molecular Pharmacology from the University of Miami, where he was a PhRMA Foundation Pre-doctoral Fellow. He conducted his post-doctoral fellowship at the National Cancer Institute in Bethesda, Maryland, where he continued as a tenure-track Senior Staff Fellow. Matthew has published extensively on the molecular events underlying cancer development, including the identification of new cancer driver pathways, which have led to novel therapeutics for cancer patients.